BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

Matinas Biopharma Holdings Inc.

Headquarters: Bedminster, NJ, United States
Year Founded: 2011
Status: Public
Industry Sector: HealthTechnology
CEO: Jerome D. Jabbour
Number Of Employees: 7
Enterprise Value: $-1,958,427
PE Ratio: -0.12
Exchange/Ticker 1: NYSE-A:MTNB
Exchange/Ticker 2: N/A
Latest Market Cap: $3,153,900

BioCentury | Feb 7, 2025
Management Tracks

Biondi becomes managing partner at Flagship

Plus: New CMOs at Epitopea and Cadrenal
BioCentury | Jan 13, 2023
Deals

J.P. Morgan deal wrap: European buyers, RNA and gene editing in spotlight

Takeouts feature CVRs to balance regulatory risk, while appetite for research collaborations remains strong in newer modalities
BioCentury | Sep 21, 2022
Management Tracks

Sharma and Lippman join Alnylam C-suite

Plus Shah now COO at Precigen and updates from Carmot, Evozyne, Matinas, Maxwell and more
BioCentury | Apr 12, 2022
Product Development

AACR data hint BioNTech on path to clearing two industry hurdles 

Early data for BNT211 show German biotech’s progress in applying CAR T cells to solid tumors, finding an effective application for cancer vaccines
BioCentury | Dec 7, 2021
Management Tracks

Biohaven names Coric chair, Buten CFO

Plus: Mutamba joins Arrakis as CBO and updates from Goldfinch, Kymera, AnHeart and more
BioCentury | Dec 3, 2020
Management Tracks

Management Tracks: Zai taps Sandler as cancer head, plus moves at FibroGen, Arena, Samumed, Avita, Mersana, Frequency, Matinas, NeuBase, Allena and RA 

Zai Lab Ltd. (NASDAQ:ZLAB; HKEX:9688) hired Alan Sandler as president, head of global development, oncology, a newly created position. Sandler was SVP and global head of product development oncology
BioCentury | Feb 25, 2019
Company News

Management tracks: Viriom, Matinas, Atreca

BioCentury | Apr 19, 2017
Company News

Management tracks

Items per page:
1 - 10 of 27